Sugi Predict

Sugi Predict / Compounds / SCHEMBL570706

SCHEMBL570706

SCHEMBL570706

O=C1CCCCc2cc(Br)ccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 9/20 0.59
▸ MAOB P27338 9/20 0.59
▸ PRKCI P41743 1/20 0.56
▸ PARP10 Q53GL7 1/20 0.53
▸ PARP11 Q9NR21 1/20 0.53
▸ HSD17B1 P14061 1/20 0.50
▸ CYP2A6 P11509 1/20 0.48
▸ GRM5 P41594 1/20 0.47
▸ SRD5A1 P18405 2/20 0.47
▸ SRD5A2 P31213 1/20 0.47
▸ BAZ2B Q9UIF8 1/20 0.46
▸ METAP1 P53582 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ CASP7 P55210 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ TDP2 O95551 1/20 0.44
▸ S100A4 P26447 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2065611 1.00 MAOA (0.59) MAOAMAOBPRKCIPARP10PARP11
SCHEMBL29521431 1.00 MAOA (0.59) MAOAMAOBPRKCIPARP10PARP11
SCHEMBL207834 0.96 MAOA (0.61) MAOAMAOBPRKCIPARP10PARP11
SCHEMBL31108080 0.88 CASP1 (0.59) MAOAMAOBPRKCIPARP10PARP11
SCHEMBL27039 0.88 CASP1 (0.59) MAOAMAOBPRKCIPARP10PARP11
SCHEMBL16313669 0.87 SRD5A1 (0.53) MAOAMAOBPRKCIPARP10PARP11
SCHEMBL23019695 0.85 MAOA (0.52) MAOAMAOBPRKCIPARP10PARP11
SCHEMBL3006544 0.84 PARP10 (0.53) MAOAMAOBPRKCIPARP10PARP11
SCHEMBL24753297 0.84 PARP10 (0.53) MAOAMAOBPRKCIPARP10PARP11
SCHEMBL29483386 0.80 MAOA (0.53) MAOAMAOBPRKCIPARP10HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545640-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2026-02-10 — — US disclosed
US-12415803-B2 Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) MERCK PATENT GMBH (DE) 2025-09-16 — — US disclosed
EP-3746064-B1 COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE BRAIN INJURY UNIV COPENHAGEN (DK) 2025-04-16 — — EP disclosed
US-20240391865-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY OTAGO INNOVATION LIMITED (NZ) 2024-11-28 — — US disclosed
US-12077495-B2 Compounds for the treatment of acute brain injury Københavns Universitet (DK) 2024-09-03 — — US disclosed
EP-3609886-B1 BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC (US) 2024-02-07 — — EP disclosed
US-11858926-B2 Inhibiting agents for bruton's tyrosine kinase BIOGEN MA INC. (US) 2024-01-02 — — US disclosed
US-11858926-B2 Inhibiting agents for bruton's tyrosine kinase BIOGEN MA INC. (US) 2024-01-02 — — US disclosed
US-11858926-B2 Inhibiting agents for bruton's tyrosine kinase BIOGEN MA INC. (US) 2024-01-02 — — US disclosed
EP-4037768-B1 NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI SA (FR) 2023-10-11 — — EP disclosed
EP-1741693-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS Nagoya Industrial Science Research Institute (JP) 2007-01-10 — — EP disclosed
EP-1110961-B1 OXYGENIC HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO KK (JP) 2004-07-14 — — EP disclosed
CN-1109029-C oxygen-containing heterocyclic compound KYOWA HAKKO KOGYO KK (JP) 2003-05-21 — — CN disclosed
US-6376535-B2 PHOSPHODIESTERASE (PDE) INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-04-23 — — US disclosed
US-20010056117-A1 Oxygen-containing heterocyclic compounds KYOWA HAKKO KIRIN CO., LTD. (JP) 2001-12-27 — — US disclosed
CN-1317002-A Oxygenic heterocyclic compounds KYOWA HAKKO KOGYO KK (JP) 2001-10-10 — — CN disclosed
EP-1110961-A1 OXYGENIC HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-06-27 — — EP disclosed
JP-2000007607-A PRODUCTION OF 7-(2-FLUOROPHENYL)-1-BENZOSUBERONE KYOWA HAKKO KOGYO CO LTD 2000-01-11 — — JP disclosed
US-4738972-A Hypoglycemic thiazolidinediones PFIZER INC. (US) 1988-04-19 — — US disclosed
US-3932430-A Substituted indeno, naphtho and cyclohepta pyrazoles SANDOZ, INC. (US) 1976-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12077495-B2 Compounds for the treatment of acute brain injury F2R, F2RL3, ARG2 MAOA 925/4885MAOB 620/4885PRKCI 3411/4885
US-20010056117-A1 Oxygen-containing heterocyclic compounds CBR1, CBR3, MT-CO1 MAOA 642/4885MAOB 572/4885PRKCI 3480/4885
US-12545640-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof ESRRA, GPER1, FSHR MAOA 620/4885MAOB 711/4885PRKCI 4640/4885
US-12415803-B2 Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) BTK, SYK, ABL1 MAOA 3594/4885MAOB 2832/4885PRKCI 182/4885
US-20240391865-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY F2R, F2RL3, ARG2 MAOA 922/4885MAOB 654/4885PRKCI 3384/4885
US-11858926-B2 Inhibiting agents for bruton's tyrosine kinase ABL1, BTK, LYN MAOA 2068/4885MAOB 1204/4885PRKCI 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.